Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic antiphospholipid syndrome.

Y Shoenfeld1

  • 1Center for Autoimmune Diseases, Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel. shoenfel@post.tau.ac.il

Lupus
|August 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion.

Arthritis and rheumatism·1996
Same author

Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.

Israel journal of medical sciences·1996
Same author

Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Circulation·1996
Same author

Guillain-Barré as an autoimmune disease.

International archives of allergy and immunology·1996
Same author

Induction of thyroid autoantibodies in naive mice by idiotypic manipulation.

Clinical immunology and immunopathology·1996
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
Same journal

Recent advances in the management of pediatric neuropsychiatric lupus from conventional therapies to novel immunomodulators.

Lupus·2026
Same journal

Association of serum and urinary galectin-3 with renal fibrosis in patients with lupus nephritis: A cross-sectional controlled study.

Lupus·2026
Same journal

Continuation of belimumab in patients with systemic lupus erythematosus in a real-world setting: A single-center retrospective cohort study.

Lupus·2026
See all related articles

Antiphospholipid syndrome (APS) is a systemic condition affecting multiple organs. Researchers propose adding "systemic" to its name, mirroring "systemic lupus erythematosus," to reflect its widespread impact.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Antiphospholipid syndrome (APS) emerged in the early 1980s, initially defined by a triad of clinical features.
  • APS has evolved into a highly systemic condition with potential involvement of nearly every organ system.
  • Recognizing its broad systemic nature is crucial for comprehensive patient care and understanding.

Purpose of the Study:

  • To propose renaming Antiphospholipid Syndrome to "Systemic Antiphospholipid Syndrome."
  • To emphasize the multisystemic nature of the disease in scientific and clinical discourse.
  • To align nomenclature with similar systemic autoimmune conditions like Systemic Lupus Erythematosus.

Main Methods:

  • Literature review of APS manifestations and systemic involvement.

Related Experiment Videos

  • Comparative analysis of nomenclature in related autoimmune diseases.
  • Clinical case review highlighting diverse organ system impact.

    • Main Results:

    • APS is characterized by widespread thrombotic and obstetric events.
    • Extensive literature confirms involvement of the brain, heart, placenta, endocrine system, blood, and kidneys.
    • The term "systemic" accurately reflects the pervasive nature of APS.

    Conclusions:

    • The current understanding of APS underscores its profound systemic impact.
    • Renaming APS to Systemic Antiphospholipid Syndrome would better represent its clinical reality.
    • Adopting "Systemic Antiphospholipid Syndrome" enhances clarity and aligns with established terminology for systemic autoimmune diseases.